Nedocromil

Nedocromil
Systematic (IUPAC) name


9-ethyl-4,6-dioxo-10-propyl-6,9-dihydro-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylic acid
Clinical data
Trade names	Alocril
AHFS/Drugs.com	monograph
MedlinePlus	a601243
Legal status	UK: POM (Prescription only) US: ℞-only
Routes of administration	Inhalation and eye drops
Pharmacokinetic data
Protein binding	89%
Metabolism	not metabolized
Biological half-life	~3.3 hours
Excretion	excreted unchanged
Identifiers
CAS Number	69049-73-6^Y
ATC code	R01AC07 R03BC03, S01GX04
PubChem	CID 50294
IUPHAR/BPS	7607
DrugBank	DB00716^Y
ChemSpider	45608^Y
UNII	0B535E0BN0^Y
KEGG	D05129^Y
ChEBI	CHEBI:7492^Y
ChEMBL	CHEMBL746^Y
Chemical data
Formula	C₁₉H₁₇NO₇
Molar mass	371.341 g/mol
SMILES O=C\1c3c(N(/C(C(=O)O)=C/1)CC)c(c2O/C(=C\C(=O)c2c3)C(=O)O)CCC
InChI InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)^Y Key:RQTOOFIXOKYGAN-UHFFFAOYSA-N^Y
(verify)

Nedocromil sodium is a medication considered as mast cell stabilizer which act to prevent wheezing, shortness of breath, and other breathing problems caused by asthma. It is administered by an inhaler under the brand name Tilade (although its effects in this form are far less than those in albuterol or other well-known inhaler medications) and as an eye drop under the brand name Alocril.^[1]^[2] Liquid preparations are available in the UK under the name Rapitil for use for allergic eye reactions.^[3]

Nedocromil is classified as a benzopyrone. Nedocromil acts as a mast cell stabilizer, inhibits the degranulation of mast cells, prevents release of histamine and tryptase, so preventing the synthesis of prostaglandins and leukotrienes. US Production of inhaled nedocromil ceased in April 2008.^[4]

References

Media related to Nedocromil at Wikimedia Commons

↑ "ALOCRIL Product Information". ALLERGAN. Retrieved 17 May 2013.
↑ "ALOCRIL (nedocromil sodium) solution/ drops". NIH. Retrieved 17 May 2013.
↑ "Nedocromil eye drops". 2007-02-02. Retrieved 2009-08-04.
↑ "Questions and Answers:Phase-Out of CFC Metered-Dose Inhalers Containing flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil". Retrieved 18 September 2014.

Decongestants and other nasal preparations (R01)

Topical

Sympathomimetics, plain	Cyclopentamine Ephedrine Epinephrine Fenoxazoline Levomethamphetamine Metizoline Naphazoline Oxymetazoline Phenylephrine Propylhexedrine Tetryzoline Tramazoline Tuaminoheptane Tymazoline Xylometazoline

Antiallergic agents, excluding corticosteroids	Spaglumic acid histamine antagonists (Levocabastine Antazoline Thonzylamine) mast cell stabilizer (some are also antihistamines) (Cromoglicic acid Nedocromil Azelastine Olopatadine Lodoxamide)

Corticosteroids	Beclometasone dipropionate Betamethasone Budesonide Ciclesonide Dexamethasone Flunisolide Fluticasone Mometasone furoate Prednisolone Tixocortol Triamcinolone

Other nasal preparations	Cafaminol Calcium hexamine thiocyanate Eucalyptus oil Framycetin Hexamidine Hyaluronan Ipratropium bromide Mupirocin Retinol Ritiometan Saline water

Systemic use:
Sympathomimetics

Drugs for obstructive airway diseases: asthma/COPD (R03)

Adrenergics, inhalants

Short-acting β₂ agonists	Bitolterol Carbuterol Fenoterol Pirbuterol Procaterol Reproterol Rimiterol Salbutamol (albuterol)^#/Levosalbutamol (levalbuterol) Terbutaline Tulobuterol

Long-acting β₂ agonists (LABA)	Bambuterol Clenbuterol Formoterol/Arformoterol Salmeterol Salmefamol

Ultra-long-acting β₂ agonists	Indacaterol Olodaterol Vilanterol

Other	Epinephrine^# Hexoprenaline Isoprenaline (isoproterenol) Orciprenaline (metaproterenol)

Glucocorticoids

Anticholinergics/
muscarinic antagonist

Mast cell stabilizers

Xanthines

Eicosanoid inhibition

Leukotriene antagonists	Montelukast Pranlukast Zafirlukast

Arachidonate 5-lipoxygenase inhibitors	Baicalein^§ Caffeic acid^§ Curcumin^§ Hyperforin^§ Meclofenamate sodium^§ St John's wort^§ Zileuton

Thromboxane receptor antagonists	Ramatroban Seratrodast

Non-xanthine PDE4 inhibitors	Ibudilast Roflumilast

Others/unknown

Combination products

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Friday, September 11, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.